Misuse of Drugs Act 1971

1U.K.The following substances, namely:—

[F2Alprazolam.]
[F3Aminorex]
Benzphetamine.
[F2Bromazepam.]
[F3Brotizolam]
[F4Buprenorphine]
[F2Camazepam.]
[F5Cathine.]
[F5Cathinone.]
[F2Chlordiazepoxide.]
Chlorphentermine.
[F2Clobazam.]
[F2Clorazepic acid.]
[F2Clonazepam.]
[F2Clotiazepam.]
[F2Cloxazolam.]
[F2Delorazepam.]
[F6Dextropropoxyphene.]
[F2Diazepam.]
[F7Diethylpropion.]
[F2Estazolam.]
[F2Ethchlorvynol.]
[F2Ethinamate.]
[F2Ethyl loflazepate.]
[F5Fencamfamin.]
[F5Fenethylline.]
[F5Fenproporex.]
[F2Fludiazepam.]
[F2Flunitrazepam.]
[F2Flurazepam.]
[F2Halazepam.]
[F2Haloxazolam.]
[F84-Hydroxy-n-butyric acid]
[F2Ketazolam.]
[F2Loprazolam.]
[F2Lorazepam.]
[F2Lormetazepam.]
[F2Mazindol.]
[F2Medazepam.]
[F5Mefenorex.]
F9. . .
Mephentermine.
[F2Meprobamate.]
[F3Mesocarb]
F10. . .
[F2Methyprylone.]
[F11Midazolam.]
[F2Nimetazepam.]
[F2Nitrazepam.]
[F2Nordazepam.]
[F2Oxazepam.]
[F2Oxazolam.]
[F12Pemoline.]
F9. . .
Phendimetrazine.
[F2Phentermine.]
[F2Pinazepam.]
F9. . .
Pipradrol.
[F2Prazepam.]
F9. . .
F13. . .
[F5Pyrovalerone.]
[F2Temazepam.]
[F2Tetrazepam.]
[F2Triazolam.]
[F5N-Ethylamphetamine.]
[F14Zolpidem]

[F15(b)[F164-Androstene-3, 17-dione]
[F165-Androstene-3, 17-diol]
Atamestane.
Bolandiol.
Bolasterone.
Bolazine.
Boldenone.
Bolenol.
Bolmantalate.
Calusterone.
4-Chloromethandienone.
Clostebol.
Drostanolone.
Enestebol.
Epitiostanol.
Ethyloestrenol.
Fluoxymesterone.
Formebolone.
Furazabol.
Mebolazine.
Mepitiostane.
Mesabolone.
Mestanolone.
Mesterolone.
Methandienone.
Methandriol.
Methenolone.
Methyltestosterone.
Metribolone.
Mibolerone.
Nandrolone.
[F1719-Nor-4-Androstene-3, 17-dione]
[F1719-Nor-5-Androstene-3, 17-diol]
Norboletone.
Norclostebol.
Norethandrolone.
Ovandrotone.
Oxabolone.
Oxandrolone.
Oxymesterone.
Oxymetholone.
Prasterone.
Propetandrol.
Quinbolone.
Roxibolone.
Silandrone.
Stanolone.
Stanozolol.
Stenbolone.
Testosterone.
Thiomesterone.
Trenbolone.

(c)any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say,

(i)by further substitution at position 17 by a methyl or ethyl group;

(ii)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(iii)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(iv)by fusion of ring A with a heterocyclic system;

(d)any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above;